fbpx
Sign up now!
Don't show this again
Download the report!Continue to Site >
or wait 7 secs

Thank you for confirming your subscription!

(And remember, if ever you want to change your email preferences or unsubscribe, just click on the links at the bottom of any email.)

We’re glad you’re enjoying Pig Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.

Antimicrobial’s unique attributes explain efficacy against key SRD pathogens

Download the PDF

The efficacy of Draxxin® (tulathromycin) against key swine respiratory disease (SRD) pathogens is largely due to the antimicrobial’s ability to reach and sustain high concentrations in lung tissue, says Lucina Galina, DVM, PhD, director of swine technical services, Zoetis.

Draxxin was the first antimicrobial in a macrolide class known as triamilides. It’s a semisynthetic derivative of erythromycin developed by Zoetis scientists exclusively for veterinary use, Galina says.

This unique antimicrobial is administered as a single intramuscular (IM) injection for the treatment of SRD associated with Actinobacillus pleuropneumoniae (APP), Pasteurella multocida (PM), Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae (M. hyo). The dosage is 2.5 mg/kg bodyweight. It’s also indicated at the same dosage for the control of SRD associated with APP, PM and M. hyo in groups of pigs where SRD has been diagnosed.

The antimicrobial’s mode of activity is similar to other macrolides. It selectively binds to a large subunit of ribosomes known as 50S. Ribosomes build proteins, and the product’s binding action inhibits bacterial protein synthesis.

Highly bioavailable

Draxxin has several beneficial attributes that have been demonstrated in studies, according to Galina.

The antimicrobial is rapidly released from the IM injection site. It takes only 15 minutes for Draxxin to reach maximum plasma concentrations. “Draxxin is also an impressive 88% bioavailable,”1 she says.

When investigators sampled lungs as well as blood after IM administration of Draxxin, they found it was extensively distributed to lung tissues. “In fact, the AUC was more than 61 times greater for the lung than for plasma. AUC stands for ‘area under the curve’ and is a measure of the drug in plasma based on drug concentration and time,”2 Galina reports.

Accumulates in immune cells

“One of the antimicrobial’s most powerful attributes is its accumulation in immune cells, specifically alveolar macrophages and neutrophils.3 These are phagocytic white blood cells that are part of the immune system and fight off bacteria,” she says.

Another important characteristic is the product’s slow elimination. “The elimination half-life of Draxxin in the lungs is 6 days.That means it takes 6 days for the amount of the drug in the body to be reduced by half. That’s a very long half-life and helps prolong the drug at the site of infection,” Galina says.

“These attributes explain the antimicrobial’s efficacy against key SRD pathogens and why one injection of the antimicrobial enables pork producers to reduce mortality from SRD, reduce the need for re-treatment and improve weight gain among affected pigs,”5 she says.

 

Important Safety Information for Swine: The pre-slaughter withdrawal time for DRAXXIN in swine is 5 days. DRAXXIN should not be used in animals known to be hypersensitive to the product.  Click here to see prescribing information for Draxxin.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.


1 Benchaoui HA, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther. 2004;27:203-210.
2 Ibid.
3 Fischer CD, et al. Direct and Indirect Anti-Inflammatory Effects of Tulathromycin in Bovine Macrophages: Inhibition of CXCL-8 Secretion, Induction of Apoptosis, and Promotion of Efferocytosis. Antimicrob Agents Chemother. 2013 March ;57(3):1385-1393.
4 Benchaoui HA, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther. 2004;27:203-210.
5 Data on file, Report No. 12ORPORKAIF02, Zoetis LLC.

 

DISCOVERIES, Issue 12
Discoveries is a series of  research news reports written by the editors of Pig Health Today on behalf of the US Pork Business of Zoetis.

DXS-00042
July 2018




Posted on February 28, 2019

tags: , , ,
RELATED NEWS
  • High prevalence of PCV2 recombinants highlights importance of broad vaccine coverage

    DISCOVERIES, Issue 21: A recent analysis of porcine circovirus type 2 (PCV2) genetic sequences shows that up to 25% of field strains are recombinants of diverse genotypes, highlighting the importance of broad protection when selecting a PCV2 vaccine.

  • Ct values predict PRRS nursery mortality, can guide vaccination decisions

    DISCOVERIES, Issue 18: Obtaining cycle threshold (Ct) values based on processing fluids provides a practical way to identify neonatal pigs at risk for nursery mortality associated with PRRS and can help determine when vaccination is worthwhile.

  • Fostera® PRRS protects against diverse PRRS virus field strains

    DISCOVERIES, Issue 19: PRRS has been described as one of the most important swine diseases of the last half-century. An estimated 20% to 25% of herds are still affected, and the syndrome remains the US swine industry’s most costly disease.

  • Chimera technology offers better path to protection for PCV2

    DISCOVERIES, Issue 6: When PCV2 first became a problem in US swine herds, scientists looked at taking the immunogenic capsid gene from PCV2 and cloning it into the backbone of nonpathogenic PCV type 1 to produce a live chimeric vaccine for PCV2.




You must be logged in to edit your profile.

Share It
E. coli has been a severe disease in the pork industry for decades and continues to be prevalent, especially during the post-weaning period when maternal antibodies aren’t available to stop severe diarrhea. How can we tackle this problem?

Click an icon to share this information with your industry contacts.
Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.